Codexis Enters into Research Collaboration with Schering-Plough
News Mar 22, 2006
The collaboration will focus on improving biocatalyst productivity using Codexis' proprietary MolecularBreeding™ pharmaceutical process re-engineering platform.
Codexis will receive research funding and milestone payments upon completion of certain objectives of the research.
"We are pleased to add Schering-Plough to our list of industry-leading pharmaceutical partners," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.
"We are delighted to see a growing number of major pharmaceutical companies recognizing the competitive advantage and cost-savings value that Codexis' technology brings to the manufacturing process for clinical-scale production and product commercialization, and look forward to continued adoption of our technology across the pharmaceutical industry."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE